Please know that this decision was not made lightly nor was it based on product efficacy, safety or because of an imposed recall. Our decision to remove ZELNORM® (tegaserod) from the market is strictly a business decision. Patients will continue to have access to ZELNORM® (tegaserod) for as long as the existing supply of product remains in the trade channel. Alfasigma USA, Inc. urges patients and Health Care Providers to discuss alternative therapies that will meet patient needs. Important Safety Information
ZELNORM® ® IMPORTANT SAFETY INFORMATION (ISI) Cardiovascular Ischemic Events, Including Major Adverse Cardiovascular Events (MACE): Stroke, MI, and cardiovascular death have been reported in adults taking ZELNORM® who had an increased risk of developing an adverse cardiovascular event based on their medical history. Female patients less than 65 years of age should be assessed for a history of cardiovascular disease and cardiovascular risk factors prior to treatment with ZELNORM® (R). Suicidal Ideation and Behavior: Monitor all ZELNORM® (R)-treated patients for clinical worsening of depression and emergence of suicidal thoughts and behaviors, especially during the initial few months of treatment. Counsel family members and caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Instruct patients to immediately discontinue ZELNORM® (R) and contact their healthcare provider if their depression is persistently worse or they are experiencing emergent suicidal thoughts or behaviors. Common Adverse Reactions (incidence >2% and greater than placebo)
Use in Specific Populations
Pregnancy: Safety and effectiveness not established
Pediatric use: Safety and effectiveness not established
Geriatric use: Not indicated for patients 65 years of age and older
Severe renal conditions: Contraindicated
Moderate to severe hepatic conditions: Contraindicated
For more information, please see the Medication Guide and full Prescribing Information for ZELNORM® (R) at www.ZELNORM® (R)us.com. In order to assist Alfasigma USA, Inc. in monitoring safety, we encourage all healthcare professionals to report any adverse events to Alfasigma USA, Inc. at 1-844-639-9726 or to the FDA at 1-800-FDA-1088 or online at http://www.fda.gov/Safety/MedWatch/ . If you have any additional questions, please contact Alfasigma USA, Inc. Medical Information at 1-844-639-9726 between the hours of 8:00 a.m. and 5:00 p.m. EST.
Alfasigma USA, Inc. is the American affiliate of Alfasigma, a leading Italian pharmaceutical company. Alfasigma is present in more than 90 countries, with a workforce of around 3,000 people and 5 manufacturing plants. Alfasigma USA, Inc. distributes a portfolio of prescription nutritional products to help individuals who are suffering from GI disorders (VSL#3®) (ZELNORM®), major depressive disorder (DEPLIN®), diabetic peripheral neuropathy (METANX®), and mild cognitive impairment (CerefolinNAC®). Alfasigma USA, Inc. is building on their commitment to making 'Pharmaceuticals with Passion' in the US. For more information, please visit www.alfasigmausa.com or email [email protected]. Vice President, New Media